Humana Inc. (NYSE:HUM) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Wednesday.

Other analysts have also issued research reports about the company. Cowen and Company reiterated an “outperform” rating and issued a $230.00 target price on shares of Humana in a research note on Tuesday, April 25th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $257.00 target price on the stock in a research note on Thursday, May 25th. Leerink Swann increased their target price on Humana from $250.00 to $265.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 30th. UBS AG reiterated a “neutral” rating and issued a $237.00 target price (up previously from $205.00) on shares of Humana in a research note on Wednesday, June 28th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $230.00 target price (up previously from $221.00) on shares of Humana in a research note on Thursday, May 4th. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $236.00.

Shares of Humana (NYSE:HUM) traded up 0.04% on Wednesday, hitting $235.92. 1,013,821 shares of the stock traded hands. The firm has a market cap of $34.05 billion, a PE ratio of 24.04 and a beta of 0.91. The firm has a 50 day moving average price of $235.90 and a 200 day moving average price of $218.69. Humana has a 52-week low of $163.50 and a 52-week high of $243.74.

Humana (NYSE:HUM) last released its earnings results on Wednesday, May 3rd. The insurance provider reported $2.75 earnings per share for the quarter, topping analysts’ consensus estimates of $2.55 by $0.20. Humana had a return on equity of 14.38% and a net margin of 2.71%. The business had revenue of $13.76 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same quarter last year, the firm posted $1.86 earnings per share. On average, equities analysts forecast that Humana will post $11.15 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Humana Inc. (NYSE:HUM) Rating Lowered to Hold at BidaskClub” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/23/humana-inc-nysehum-rating-lowered-to-hold-at-bidaskclub.html.

In related news, VP Heidi S. Margulis sold 1,500 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the sale, the vice president now owns 8,150 shares of the company’s stock, valued at $1,890,474. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Timothy S. Huval sold 13,939 shares of the firm’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $225.86, for a total value of $3,148,262.54. Following the sale, the vice president now directly owns 23,639 shares in the company, valued at approximately $5,339,104.54. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 143,241 shares of company stock worth $32,446,903. 0.80% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after buying an additional 11,867,056 shares during the period. Vanguard Group Inc. boosted its stake in Humana by 3.6% in the first quarter. Vanguard Group Inc. now owns 9,734,767 shares of the insurance provider’s stock worth $2,006,725,000 after buying an additional 339,620 shares during the period. State Street Corp boosted its stake in Humana by 1.4% in the first quarter. State Street Corp now owns 6,274,811 shares of the insurance provider’s stock worth $1,293,487,000 after buying an additional 84,716 shares during the period. FMR LLC boosted its stake in Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock worth $1,041,184,000 after buying an additional 1,851,197 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock worth $554,867,000 after buying an additional 1,231,400 shares during the period. Institutional investors own 99.04% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.